MedPath

The effect of myo-inositol supplementation on NAFLD

Phase 3
Recruiting
Conditions
on-alcoholic fatty liver.
Fatty (change of) liver, not elsewhere classified
K76.0
Registration Number
IRCT20210530051441N2
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
42
Inclusion Criteria

Age 18-55 years
Body mass index = 30-40 Kg /m2
Willingness to cooperate
Hepatic steatosis based on Grade 1 and 2 NAFLD disease

Exclusion Criteria

Athlete, pregnancy, lactation and menopause in women
Smoking and drinking alcohol
Adherence to a special diet or weight loss 3 months before the study
Use of chemical or herbal medicines for weight loss, hepatotoxic (phenytoin, amoxifine, lithium), lipid-lowering (statins), Insulin sensitizer, corticosteroids and non-steroidal, anti-inflammatory medications and any dietary supplements for 3 months before the study
History of weight loss surgery over the last year
those with cardiovascular, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary, any known autoimmune diseases, PCOs, cancers and conditions with mal-absorption such as Sprue and Crohn
Candidate or history of Liver transplant

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath